Shares of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) have been given an average recommendation of “Buy” by the six brokerages that are covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $11.00.
Several research firms recently issued reports on ZYNE. ValuEngine lowered shares of Zynerba Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, February 4th. Zacks Investment Research lowered shares of Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Sunday, January 27th. HC Wainwright reaffirmed a “buy” rating on shares of Zynerba Pharmaceuticals in a report on Monday, March 18th. Finally, Cantor Fitzgerald